These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 33109706)

  • 21. Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis-a systematic review and meta-analysis.
    Luo L; Song Z; Li X; Huiwang ; Zeng Y; Qinwang ; Meiqi ; He J
    Neurol Sci; 2019 Feb; 40(2):235-241. PubMed ID: 30483992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Associations between the ALSFRS-R score and urate levels during 12 months of edaravone treatment for amyotrophic lateral sclerosis: Post hoc analysis of ALSFRS-R scores in clinical studies MCI186-16, MCI186-17, and MCI186-19.
    Takahashi F; Kano O; Nagano Y; Yoneoka T; Nelson S; Ushirogawa Y
    Muscle Nerve; 2022 Nov; 66(5):593-602. PubMed ID: 36053970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: Post hoc analysis of ALSFRS-R item scores in pivotal study MCI186-19.
    Brooks BR; Pioro EP; Katz J; Takahashi F; Takei K; Zhang J; Apple S
    Muscle Nerve; 2022 Feb; 65(2):180-186. PubMed ID: 34816454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Staging amyotrophic lateral sclerosis: A new focus on progression.
    Corcia P; Beltran S; Lautrette G; Bakkouche S; Couratier P
    Rev Neurol (Paris); 2019 May; 175(5):277-282. PubMed ID: 30606512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis.
    EDARAVONE (MCI-186) ALS 16 STUDY GROUP
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):11-19. PubMed ID: 28872917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurophysiological indices in amyotrophic lateral sclerosis correlate with functional outcome measures, staging and disease progression.
    Barp A; Lizio A; Gerardi F; Tarlarini C; Mauro L; Sansone VA; Lunetta C
    Clin Neurophysiol; 2021 Jul; 132(7):1564-1571. PubMed ID: 34023632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation).
    WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):40-48. PubMed ID: 28872915
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.
    Jaiswal MK
    Med Res Rev; 2019 Mar; 39(2):733-748. PubMed ID: 30101496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of intervention with intravenous edaravone in Study 19 on hospitalization, tracheostomy, ventilation, and death in patients with amyotrophic lateral sclerosis.
    Brooks BR; Pioro EP; Sakata T; Takahashi F; Hagan M; Apple S
    Muscle Nerve; 2023 Oct; 68(4):397-403. PubMed ID: 37525592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study.
    Fang T; Al Khleifat A; Meurgey JH; Jones A; Leigh PN; Bensimon G; Al-Chalabi A
    Lancet Neurol; 2018 May; 17(5):416-422. PubMed ID: 29525492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health-related quality of life across disease stages in patients with amyotrophic lateral sclerosis: results from a real-world survey.
    Stenson K; Fecteau TE; O'Callaghan L; Bryden P; Mellor J; Wright J; Earl L; Thomas O; Iqbal H; Barlow S; Parvanta S
    J Neurol; 2024 May; 271(5):2390-2404. PubMed ID: 38200398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Edaravone and its clinical development for amyotrophic lateral sclerosis.
    Takei K; Watanabe K; Yuki S; Akimoto M; Sakata T; Palumbo J
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):5-10. PubMed ID: 28872907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Edaravone for the treatment of amyotrophic lateral sclerosis.
    Yoshino H
    Expert Rev Neurother; 2019 Mar; 19(3):185-193. PubMed ID: 30810406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System.
    Vu M; Tortorice K; Zacher J; Dong D; Hur K; Zhang R; Good CB; Glassman PA; Cunningham FE
    JAMA Netw Open; 2020 Oct; 3(10):e2014645. PubMed ID: 33017028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Healthcare resource utilization at different stages of amyotrophic lateral sclerosis: Results from a real-world survey.
    Stenson K; O'Callaghan L; Mellor J; Wright J; Gibson G; Earl L; Barlow S; Fournier CN
    J Neurol Sci; 2023 Sep; 452():120764. PubMed ID: 37639764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of edaravone compared to historical controls in patients with amyotrophic lateral sclerosis from North-Eastern Italy.
    Fortuna A; Gizzi M; Bello L; Martinelli I; Bertolin C; Pegoraro E; Corbetta M; Sorarù G;
    J Neurol Sci; 2019 Sep; 404():47-51. PubMed ID: 31325668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disease survival and progression in TARDBP ALS patients from Sardinia, Italy.
    Borghero G; Pili F; Muroni A; Ercoli T; Pateri MI; Pilotto S; Maccabeo A; Defazio G
    J Neurol; 2024 Feb; 271(2):929-934. PubMed ID: 37855870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early post-marketing experience with edaravone in an unselected group of patients with ALS.
    Abraham A; Nefussy B; Fainmesser Y; Ebrahimi Y; Karni A; Drory VE
    Amyotroph Lateral Scler Frontotemporal Degener; 2019 May; 20(3-4):260-263. PubMed ID: 30784320
    [No Abstract]   [Full Text] [Related]  

  • 39. Intuitive Staging Correlates With King's Clinical Stage.
    Al Khleifat A; Balendra R; Fang T; Al-Chalabi A
    Amyotroph Lateral Scler Frontotemporal Degener; 2021 Aug; 22(5-6):336-340. PubMed ID: 33821690
    [No Abstract]   [Full Text] [Related]  

  • 40. The progressive loss of brain network fingerprints in Amyotrophic Lateral Sclerosis predicts clinical impairment.
    Romano A; Trosi Lopez E; Liparoti M; Polverino A; Minino R; Trojsi F; Bonavita S; Mandolesi L; Granata C; Amico E; Sorrentino G; Sorrentino P
    Neuroimage Clin; 2022; 35():103095. PubMed ID: 35764029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.